Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: Data from the Italian cohort of the ATHENA trial.

Sanna G, Fabi A, Crivellari D, Saracchini S, Battelli N, Nisticò C, Capobianco AM, Zampa G, Bottini A, Del Prete S, Simoncini E, Galli A, Matasconi M, Restuccia E, Biganzoli L.

Tumori. 2014 Jul-Aug;100(4):432-8. doi: 10.1700/1636.17904.

PMID:
25296593
[PubMed - in process]
2.

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.

Fabi A, Merola R, Ferretti G, Di Benedetto A, Antoniani B, Ercolani C, Nisticò C, Papaldo P, Ciccarese M, Sperduti I, Vici P, Marino M, Gori S, Botti C, Malaguti P, Cognetti F, Mottolese M.

Expert Opin Pharmacother. 2013 Apr;14(6):699-706. doi: 10.1517/14656566.2013.779672. Epub 2013 Mar 9.

PMID:
23472669
[PubMed - indexed for MEDLINE]
3.

p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes.

Prodosmo A, De Amicis A, Nisticò C, Gabriele M, Di Rocco G, Monteonofrio L, Piane M, Cundari E, Chessa L, Soddu S.

J Clin Invest. 2013 Mar 1;123(3):1335-42. doi: 10.1172/JCI67289. Epub 2013 Feb 1.

PMID:
23454770
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F.

BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482.

PMID:
23083011
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Orthorexia nervosa: a frequent eating disordered behavior in athletes.

Segura-García C, Papaianni MC, Caglioti F, Procopio L, Nisticò CG, Bombardiere L, Ammendolia A, Rizza P, De Fazio P, Capranica L.

Eat Weight Disord. 2012 Dec;17(4):e226-33. doi: 10.3275/8272. Epub 2012 Feb 21.

PMID:
22361450
[PubMed - indexed for MEDLINE]
6.

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.

Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nisticò C, Russillo M, Papaldo P, Ferretti G, Aapro M, Giannarelli D, Cognetti F.

J Exp Clin Cancer Res. 2011 May 12;30:54. doi: 10.1186/1756-9966-30-54.

PMID:
21569417
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.

Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P, Cognetti F, Mottolese M.

Clin Cancer Res. 2011 Apr 1;17(7):2055-64. doi: 10.1158/1078-0432.CCR-10-1920. Epub 2011 Feb 9.

PMID:
21307144
[PubMed - indexed for MEDLINE]
Free Article
8.

Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials.

Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nisticò C, Ruggeri EM, Sperduti I, Bracarda S, Pinnarò P, Lanzetta G, Muti P, Cognetti F, Carlini P.

BMC Cancer. 2010 Dec 9;10:675. doi: 10.1186/1471-2407-10-675.

PMID:
21143897
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

Fabi A, Metro G, Di Benedetto A, Nisticò C, Vici P, Melucci E, Antoniani B, Perracchio L, Sperduti I, Milella M, Cognetti F, Mottolese M.

Oncology. 2010;78(2):141-9. doi: 10.1159/000312656. Epub 2010 Apr 13.

PMID:
20389136
[PubMed - indexed for MEDLINE]
10.

Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.

Nisticò C, Bria E, Vaccaro V, Cuppone F, Fornier M, Sperduti I, Carpino A, Izzo F, Tropea F, Cognetti F, Terzoli E.

Anticancer Drugs. 2009 Feb;20(2):109-14. doi: 10.1097/CAD.0b013e32831bc09b.

PMID:
19209027
[PubMed - indexed for MEDLINE]
11.

Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues.

Bria E, Cuppone F, Milella M, Verma S, Carlini P, Nisticò C, Vaccaro V, Rossi A, Tonini G, Cognetti F, Terzoli E.

Expert Opin Biol Ther. 2008 Dec;8(12):1963-71. doi: 10.1517/14728220802517935 .

PMID:
18990083
[PubMed - indexed for MEDLINE]
12.

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.

Breast Cancer Res. 2008;10(5):R74. doi: 10.1186/bcr2139. Epub 2008 Sep 4.

PMID:
18771580
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials.

Cuppone F, Bria E, Carlini P, Milella M, Felici A, Sperduti I, Nisticò C, Terzoli E, Cognetti F, Giannarelli D.

Cancer. 2008 Jul 15;113(2):238-46. doi: 10.1002/cncr.23544.

PMID:
18470908
[PubMed - indexed for MEDLINE]
Free Article
14.

Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.

Folgiero V, Avetrani P, Bon G, Di Carlo SE, Fabi A, Nisticò C, Vici P, Melucci E, Buglioni S, Perracchio L, Sperduti I, Rosanò L, Sacchi A, Mottolese M, Falcioni R.

PLoS One. 2008 Feb 13;3(2):e1592. doi: 10.1371/journal.pone.0001592.

PMID:
18270579
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.

Cuppone F, Bria E, Verma S, Pritchard KI, Gandhi S, Carlini P, Milella M, Nisticò C, Terzoli E, Cognetti F, Giannarelli D.

Cancer. 2008 Jan 15;112(2):260-7.

PMID:
18041059
[PubMed - indexed for MEDLINE]
Free Article
16.

Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.

Nisticò C, Bria E, Cuppone F, Fornier M, Sperduti I, Carpino A, Pace A, Cognetti F, Terzoli E.

Anticancer Drugs. 2007 Jul;18(6):687-92.

PMID:
17762397
[PubMed - indexed for MEDLINE]
17.

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.

Bria E, Cuppone F, Fornier M, Nisticò C, Carlini P, Milella M, Sperduti I, Terzoli E, Cognetti F, Giannarelli D.

Breast Cancer Res Treat. 2008 May;109(2):231-9. Epub 2007 Jul 19. Review.

PMID:
17638068
[PubMed - indexed for MEDLINE]
18.

Aromatase inhibitors in post-menopausal metastatic breast carcinoma.

Carlini P, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Ruggeri EM, Milella M, Nuzzo C, Cecere FL, Gelibter A, Pino MS, Nisticò C, Cuppone F, Metro G, Terzoli E, Cognetti F, Ferretti G.

Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36. Review.

PMID:
17594187
[PubMed - indexed for MEDLINE]
19.

Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.

Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nisticò C, Terzoli E, Cognetti F, Giannarelli D.

Cancer. 2007 Aug 1;110(3):525-33.

PMID:
17577216
[PubMed - indexed for MEDLINE]
Free Article
20.

Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?

Pace A, Nisticò C, Cuppone F, Bria E, Galiè E, Graziano G, Natoli G, Sperduti I, Jandolo B, Calabretta F, Tomao S, Terzoli E.

Clin Breast Cancer. 2007 Apr;7(7):550-4.

PMID:
17509163
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk